Paracetamol, chlorpheniramine and pseudoephedrine for cold

The common cold is a self-limiting yet highly burdensome condition, and treatment is exclusively symptomatic, aiming to alleviate discomfort while the immune system clears the infection. A widely utilised approach involves combination therapies, and among these, the triad of paracetamol, chlorpheniramine (a first-generation antihistamine), and pseudoephedrine (a decongestant) represents a common pharmacological strategy.

Paracetamol

The rationale for this combination lies in targeting the multifaceted nature of cold symptoms through distinct mechanisms of action. Paracetamol provides an antipyretic and analgesic effect, effectively reducing fever and alleviating the associated headaches and muscle pains that result from the systemic inflammatory response and prostaglandin synthesis triggered by the viral infection. This systemic relief is a crucial component of improving a patient’s overall sense of well-being.

Chlorpheniramine

Chlorpheniramine operates through a dual mechanism to address local nasal symptoms. Primarily, as a potent inverse agonist of the histamine H1 receptor with significant anticholinergic properties, it acts on the central nervous system to reduce the sneeze reflex and dampen glandular secretions, thereby alleviating rhinorrhoea. Evidence from meta-analyses suggests that while its efficacy as a monotherapy may be modest, it offers statistically significant benefits in reducing sneezing and runny nose severity within the first 48 hours of treatment compared to placebo. Its sedative side effect can also be perceived as beneficial for restoring sleep disrupted by cold symptoms.

Pseudoephedrine

Pseudoephedrine completes the combination by specifically targeting nasal congestion, often the most bothersome symptom. As a sympathomimetic amine, it acts as an agonist on α-adrenergic receptors, inducing vasoconstriction in the nasal mucosa’s cavernous vein plexus. This reduces swelling and vascular permeability, thereby improving nasal airflow. Clinical trials indicate that its efficacy is most pronounced in the short term, providing subjective relief from nasal obstruction, though its effect can be variable depending on dosage and individual response.

Paracetamol provides an antipyretic and analgesic effect, reducing fever and alleviating the headaches and muscle pains that result from the systemic inflammatory response and prostaglandin synthesis.

Combination approach

The theoretical synergy of this combination is clear: three primary symptom clusters are addressed simultaneously. However, this polypharmacy approach necessitates a careful consideration of the associated safety profiles. The most common adverse effects are generally mild; chlorpheniramine is associated with drowsiness, dry mouth, and sedation, while pseudoephedrine can cause central nervous system stimulation, leading to insomnia, nervousness, and palpitations. The inclusion of paracetamol is generally well-tolerated but carries a well-documented risk of hepatotoxicity at supratherapeutic doses.

There are a few rare adverse drug reactions. Pseudoephedrine, due to its vasoconstrictive properties, has been implicated in case reports of serious cardiac and neurovascular events, including myocardial infarction, stroke, and posterior reversible encephalopathy syndrome (PRES), which has prompted recent regulatory safety reviews in Europe. Chlorpheniramine carries a proarrhythmic potential, primarily through the blockade of cardiac hERG potassium channels, which can rarely lead to QT prolongation and torsades de pointes, particularly in overdose or in susceptible individuals.

This combination is contraindicated in individuals with severe or uncontrolled hypertension, cardiovascular disease, severe renal impairment, or those taking monoamine oxidase inhibitor, and should be used with caution in the elderly and individuals with glaucoma and enlarged prostate.

In conclusion, while the acetaminophen, chlorpheniramine, and pseudoephedrine combination offers a broad-spectrum symptomatic relief strategy for adults suffering from the common cold, its use should be informed by an awareness of potential side effects and a clear understanding of patient contraindications, favouring short-term use at recommended doses.

REFERENCES

Douhard, R, et al, 2024. Pharmacology of chlorphenamine and pseudoephedrine use in the common cold: a narrative review. Curr Med Res Opin. 2024 Dec;40(12):2125-2137.